1
|
Knap-Wielgus W, Zygula A, Malec M, Wielgos M, Szymusik I. The Polish women's experience and level of knowledge about fertility and its disorders - a cross-sectional study. Ginekol Pol 2023:VM/OJS/J/91278. [PMID: 37162137 DOI: 10.5603/gp.a2023.0047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Revised: 12/12/2022] [Accepted: 02/08/2023] [Indexed: 05/11/2023] Open
Abstract
OBJECTIVES To assess the experience and knowledge of Polish women up to 50 years of age about fertility and its disorders. MATERIAL AND METHODS A self-composed questionnaire consisting of 44 questions, divided into six sections, was available in social media from January until February 2020. The answers to 13 single-choice questions were analyzed to assess the level of knowledge. Statistical analysis was performed with the use of Statistica 13.0, with p value < 0.05 considered significant. RESULTS A total of 3,321 correctly filled out questionnaires were obtained. The average result was 8.88 out of 13 single-choice questions regarding the basics of the menstrual cycle and infertility (median 9, standard deviation [SD] 2.21). As many as 65.2% of respondents did not know which days in the cycle were fertile days. The women who had been and/or were pregnant at the time of survey, more often answered better than those, who had never given birth. They had a better mean score of 13 single-choice questions compared to those who had never been pregnant (9.02 vs 8.61, p < 0.001). Respondents who obtained information about infertility from doctors in 86.97% knew that regular intercourse meant 2-3 times per week in comparison to 79.7% of those who were not educated by medical practitioners (p < 0.0001). 69.8% respondents from the first group knew that the test of ovarian reserve existed in comparison to 55.63% of women from the second group (p < 0.0001). CONCLUSIONS The research has shown that the knowledge about fertility and its disorders is not satisfying among Polish women.
Collapse
Affiliation(s)
| | | | - Magdalena Malec
- Department of History of Medicine, Medical University of Warsaw, Poland
| | | | - Iwona Szymusik
- Department of Obstetrics, Perinatology and Neonatology, the Center of Postgraduate Medical Education, Warsaw, Poland
| |
Collapse
|
2
|
Wu M, Malec M, Wroblewski K, Barry T, Opalecky B, Kindler H. EP07.01-013 Physical Function, Symptom Burden, and Quality of Life in Patients with Malignant Pleural Mesothelioma. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
3
|
Sobiak J, Głyda M, Malec M, Chrzanowska M. Pharmacokinetics of Mycophenolate Mofetil Metabolites in Older Patients on the Seventh Day After Renal Transplantation. Transplant Proc 2021; 53:2212-2215. [PMID: 34412913 DOI: 10.1016/j.transproceed.2021.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 07/19/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Currently, immunosuppression schemes are age-independent; however, physiological changes may alter drugs' pharmacokinetics in the older population. We compared mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) pharmacokinetics among patients aged <60 and >60 years on the seventh day after renal transplantation. METHODS We included 7 and 10 renal transplant recipients, aged >60 and <60 years, respectively, treated with mycophenolate mofetil. MPA and MPAG concentrations were determined using the high-performance liquid chromatography method with ultraviolet detection (HPLC-UV). Noncompartmental pharmacokinetic analysis was performed. RESULTS In patients aged >60 years, mean MPA and MPAG concentrations before the next dose and ratio of MPAG area under the concentration-time curve (AUC0-12) to MPA AUC0-12 were higher by 1.6-fold, 1.4-fold, and 1.9-fold, respectively. Other MPAG concentrations appeared to be slightly higher (1.2- to 1.5-fold) in older patients. MPA apparent clearance was similar in both groups, whereas volume of distribution at steady state was slightly higher (1.6-fold) in patients aged >60 years. The variability of most MPA and some MPAG pharmacokinetics was greater in patients aged >60 years. The MPA AUC0-12 target was achieved in 40% and 14% of patients aged <60 and >60 years, respectively. The highest MPAG concentrations and AUC0-12 were observed for patients with the lowest glomerular filtration rate. CONCLUSIONS Higher variability of MPA and MPAG pharmacokinetic parameters, MPA AUC0-12 above the reference range, higher values of MPAG pharmacokinetics in patients with lower glomerular filtration rates, as well as lower proportion of patients achieving MPA targets all indicate the need for therapeutic drug monitoring in renal transplant recipients aged >60 years and to verify target MPA AUC0-12 for this population.
Collapse
Affiliation(s)
- J Sobiak
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznań, Poland.
| | - M Głyda
- Department of Transplantology and General Surgery, Poznań District Hospital, Poznań, Poland; Department of Hepatobiliary and General Surgery, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland
| | - M Malec
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznań, Poland
| | - M Chrzanowska
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznań, Poland
| |
Collapse
|
4
|
Kuźnar-Kamińska B, Mikuła-Pietrasik J, Mały E, Makowska N, Malec M, Tykarski A, Batura-Gabryel H, Książek K. Serum from patients with chronic obstructive pulmonary disease promotes proangiogenic behavior of the vascular endothelium. Eur Rev Med Pharmacol Sci 2019; 22:7470-7481. [PMID: 30468496 DOI: 10.26355/eurrev_201811_16288] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE It has been documented that COPD is a risk factor for lung cancer. In COPD patients, changes in lung angiogenesis - a critical process in the development of lung cancer - have been poorly investigated. We aimed to determine whether serum from COPD patients could promote the proangiogenic capabilities of endothelial cells in vitro. PATIENTS AND METHODS The research was carried out using sera from COPD patients and healthy volunteers, endothelial cells EA.hy926, and bronchial epithelial cells. The concentration of angiogenic molecules was quantified using ELISA tests. The proliferation and migration of EA.hy926 were tested using fluorescence-based methods. Tube formation was analyzed with a commercially available assay. RESULTS Sera from COPD patients and conditioned media generated by epithelial cells exposed to these sera stimulate proliferation, but not migration, of EA.hy926. This coincided with increased tube formation in both experimental regimens. The sera from COPD patients contained increased levels of CCL2, CCL21, and HGF, whereas the conditioned media generated by epithelial cells treated with these sera exhibited increased levels of CCL2, CCL21, CXCL8, FGF, and sICAM-1. The concentration of angiogenic markers in the sera and conditioned media, and their effect on the behavior of the endothelium were independent of smoking status (COPD and controls), stage of obstruction, and disease group (COPD). CONCLUSIONS The increased incidence of lung malignancy in COPD patients may be associated, at least to some extent, with the direct and indirect proangiogenic activity of their sera (via alterations in the secretome of epithelial cells).
Collapse
Affiliation(s)
- B Kuźnar-Kamińska
- Department of Pulmonology, Allergology, and Respiratory Oncology, Poznań University of Medical Sciences, Poznań, Poland.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Malec M, Smektala T, Tutak M, Trybek G, Sporniak-Tutak K. Maxillary Sinus Septa Prevalence and Morphology: Computed Tomography Based Analysis. INT J MORPHOL 2015. [DOI: 10.4067/s0717-95022015000100023] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Malec M, Smektała T, Trybek G, Sporniak-Tutak K. Maxillary sinus septa: prevalence, morphology, diagnostics and implantological implications. Systematic review. Folia Morphol (Warsz) 2014. [DOI: 10.5603/fm.2014.0041] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Lukas RV, Rezania K, Malec M, Salgia R. Teaching Video NeuroImages: Myokymia and nerve hyperexcitability as components of Morvan syndrome due to malignant thymoma. Neurology 2013; 80:e55. [DOI: 10.1212/wnl.0b013e31827f0fa1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
8
|
Düster P, Dommermuth E, Rüthlein HJ, Fischer U, Lehrmann M, Malec M. [Primary and secondary intussuception of the small intestine in adults. Two case reports]. MMW Fortschr Med 2009; 151:57-58. [PMID: 19771796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Affiliation(s)
- P Düster
- FA für Allgemein-, Thorax- und Viszeralchirurgie, St. Nikolaus-Stiftshospital Andernach, Akademisches Lehrkrankenhaus der Univ. Bonn.
| | | | | | | | | | | |
Collapse
|
9
|
Garhöfer G, Kopf A, Polska E, Malec M, Dorner GT, Wolzt M, Schmetterer L. Influence of exercise induced hyperlactatemia on retinal blood flow during normo- and hyperglycemia. Curr Eye Res 2009; 28:351-8. [PMID: 15287372 DOI: 10.1076/ceyr.28.5.351.28680] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
PURPOSE Short term hyperglycemia has previously been shown to induce a blood flow increase in the retina. The mechanism behind this effect is poorly understood. We set out to investigate whether exercise-induced hyperlactatemia may alter the response of retinal blood flow to hyperglycemia. METHODS We performed a randomized, controlled two-way cross over study comprising 12 healthy subjects, performed a 6-minutes period of dynamic exercise during an euglcaemic or hyperglycaemic insulin clamp. Retinal blood flow was assessed by combined vessel size measurement with the Zeiss retinal vessel analyzer and measurement of red blood cell velocities using bi-directional laser Doppler velocimetry. Retinal and systemic hemodynamic parameters were measured before, immediately after and 10 and 20 minutes after isometric exercise. RESULTS On the euglycemic study day retinal blood flow increased after dynamic exercise. The maximum increase in retinal blood flow was observed 10 minutes after the end of exercise when lactate plasma concentration peaked. Hyperglycemia increased retinal blood flow under basal conditions, but had no incremental effect during exercise induced hyperlactatemia. CONCLUSIONS Our results indicate that both lactate and glucose induce an increase in retinal blood flow in healthy humans. This may indicate a common pathway between glucose and lactate induced blood flow changes in the human retina.
Collapse
Affiliation(s)
- Gerhard Garhöfer
- Department of Clinical Pharmacology, University of Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
10
|
Drews K, Seremak-Mrozikiewicz A, Puk E, Kaluba-Skotarczak A, Malec M, Kazikowska A. [The safety and tolerance of isoflavones (Soyfem) administration in postmenopausal women]. Ginekol Pol 2007; 78:361-5. [PMID: 17867326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/17/2023] Open
Abstract
INTRODUCTION In recent years, considerable attention has been paid to isoflavones and their proprieties to alleviate the climacteric symptoms. The goal of this study was to evaluate the efficacy of standardized isoflavones extract (Soyfem) in moderate and medium-severe climacteric syndrome. MATERIAL AND METHODS 555 postmenopausal women were recruited for the study. Out of this group, 169 women completed the study (12-month observation period). The patients were classified according to the intensity of climacteric symptoms (< or =34 points in Kupperman index). 1 or 2 tablets of Soyfem were administered twice a day,. RESULTS A regular decrease of Kupperman index value and improvement of life quality were observed in the group of 169 postmenopausal women. We have noted a decrease in the intensity and number of hot flushes, diaphoresis (p < 0.05), diminished sleep disturbances (p < 0.05), decreased headache, dizziness, and arthrosis pain. The diminished intensity of tiredness, palpitation and breathlessness have been also observed (p < 0.05). 80% of all investigated women noted the regression of paresthesis, 20% indicated the decreased number of paresthesis (p < 0.05). Influence of Soyfem on the variability and moderation of depressive mood (p < 0.05) have been also positive evaluated by patients. CONCLUSIONS Administration of Soyfem in the dosage 52 to 104 mg/24 hours (2 times daily 1 or 2 tablets) is a safe and effective therapy in the postmenopausal women with moderate and medium-severe climacteric syndrome evaluated according to the Kupperman index. Administration of Soyfem is connected with a good compliance and correlated with well-being in the investigated women allowing a long-term administration.
Collapse
Affiliation(s)
- Krzysztof Drews
- Klinika Perinatologii i Chorób Kobiecych, Katedra Perinatologii i Ginekologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.
| | | | | | | | | | | |
Collapse
|
11
|
Drews K, Seremak-Mrozikiewicz A, Puk E, Kaluba-Skotarczak A, Malec M, Kazikowska A. [Efficacy of standardized isoflavones extract (Soyfem) (52-104 mg/24h) in moderate and medium-severe climacteric syndrome]. Ginekol Pol 2007; 78:307-11. [PMID: 17621994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023] Open
Abstract
INTRODUCTION In recent years, considerable attention has been paid to isoflavones and their proprieties to alleviate the climacteric symptoms. The goal of this study was to evaluate the efficacy of standardized isoflavones extract (Soyfem) in moderate and medium-severe climacteric syndrome. MATERIAL AND METHODS 555 postmenopausal women were recruited for the study. Out of this group, 169 women completed the study (12-month observation period). The patients were classified according to the intensity of climacteric symptoms (< or = 34 points in Kupperman index). 1 or 2 tablets of Soyfem were administered twice a day. RESULTS A regular decrease of Kupperman index value and improvement of life quality were observed in the group of 169 postmenopausal women. We have noted a decrease in the intensity and number of hot flushes, diaphoresis (p < 0.05), diminished sleep disturbances (p < 0.05), decreased headache, dizziness, and arthrosis pain. The diminished intensity of tiredness, palpitation and breathlessness have been also observed (p < 0.05). 80% of all investigated women noted the regression of paresthesis, 20% indicated the decreased number of paresthesis (p < 0.05). Influence of Soyfem on the variability and moderation of depressive mood (p < 0.05) have been also positive evaluated by patients. CONCLUSIONS Administration of Soyfem in the dosage 52 to 104 mg/24 hours (2 times daily 1 or 2 tablets) is a safe and effective therapy in the postmenopausal women with moderate and medium-severe climacteric syndrome evaluated according to the Kupperman index. Administration of Soyfem is connected with a good compliance and correlated with well-being in the investigated women allowing a long-term administration.
Collapse
Affiliation(s)
- Krzysztof Drews
- Klinika Perinatologii i Chorób Kobiecych, Katedra Perinatologii i Ginekologii, Uniwersytetu Medycznego w Poznaniu.
| | | | | | | | | | | |
Collapse
|
12
|
Abbott B, Abbott R, Adhikari R, Agresti J, Ajith P, Allen B, Allen J, Amin R, Anderson SB, Anderson WG, Araya M, Armandula H, Ashley M, Aulbert C, Babak S, Balasubramanian R, Ballmer S, Barish BC, Barker C, Barker D, Barton MA, Bayer K, Belczynski K, Betzwieser J, Bhawal B, Bilenko IA, Billingsley G, Black E, Blackburn K, Blackburn L, Bland B, Bogue L, Bork R, Bose S, Brady PR, Braginsky VB, Brau JE, Brown DA, Buonanno A, Busby D, Butler WE, Cadonati L, Cagnoli G, Camp JB, Cannizzo J, Cannon K, Cardenas L, Carter K, Casey MM, Charlton P, Chatterji S, Chen Y, Chin D, Christensen N, Cokelaer T, Colacino CN, Coldwell R, Cook D, Corbitt T, Coyne D, Creighton JDE, Creighton TD, Dalrymple J, D'Ambrosio E, Danzmann K, Davies G, DeBra D, Dergachev V, Desai S, DeSalvo R, Dhurandar S, Díaz M, Di Credico A, Drever RWP, Dupuis RJ, Ehrens P, Etzel T, Evans M, Evans T, Fairhurst S, Finn LS, Franzen KY, Frey RE, Fritschel P, Frolov VV, Fyffe M, Ganezer KS, Garofoli J, Gholami I, Giaime JA, Goda K, Goggin L, González G, Gray C, Gretarsson AM, Grimmett D, Grote H, Grunewald S, Guenther M, Gustafson R, Hamilton WO, Hanna C, Hanson J, Hardham C, Harry G, Heefner J, Heng IS, Hewitson M, Hindman N, Hoang P, Hough J, Hua W, Ito M, Itoh Y, Ivanov A, Johnson B, Johnson WW, Jones DI, Jones G, Jones L, Kalogera V, Katsavounidis E, Kawabe K, Kawamura S, Kells W, Khan A, Kim C, King P, Klimenko S, Koranda S, Kozak D, Krishnan B, Landry M, Lantz B, Lazzarini A, Lei M, Leonor I, Libbrecht K, Lindquist P, Liu S, Lormand M, Lubinski M, Lück H, Luna M, Machenschalk B, MacInnis M, Mageswaran M, Mailand K, Malec M, Mandic V, Marka S, Maros E, Mason K, Matone L, Mavalvala N, McCarthy R, McClelland DE, McHugh M, McNabb JWC, Melissinos A, Mendell G, Mercer RA, Meshkov S, Messaritaki E, Messenger C, Mikhailov E, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Miyakawa O, Mohanty S, Moreno G, Mossavi K, Mueller G, Mukherjee S, Myers E, Myers J, Nash T, Nocera F, Noel JS, O'Reilly B, O'Shaughnessy R, Ottaway DJ, Overmier H, Owen BJ, Pan Y, Papa MA, Parameshwaraiah V, Parameswariah C, Pedraza M, Penn S, Pitkin M, Prix R, Quetschke V, Raab F, Radkins H, Rahkola R, Rakhmanov M, Rawlins K, Ray-Majumder S, Re V, Regimbau T, Reitze DH, Riesen R, Riles K, Rivera B, Robertson DI, Robertson NA, Robinson C, Roddy S, Rodriguez A, Rollins J, Romano JD, Romie J, Rowan S, Rüdiger A, Ruet L, Russell P, Ryan K, Sandberg V, Sanders GH, Sannibale V, Sarin P, Sathyaprakash BS, Saulson PR, Savage R, Sazonov A, Schilling R, Schofield R, Schutz BF, Schwinberg P, Scott SM, Seader SE, Searle AC, Sears B, Sellers D, Sengupta AS, Shawhan P, Shoemaker DH, Sibley A, Siemens X, Sigg D, Sintes AM, Smith J, Smith MR, Spjeld O, Strain KA, Strom DM, Stuver A, Summerscales T, Sung M, Sutton PJ, Tanner DB, Taylor R, Thorne KA, Thorne KS, Tokmakov KV, Torres C, Torrie C, Traylor G, Tyler W, Ugolini D, Ungarelli C, Vallisneri M, van Putten M, Vass S, Vecchio A, Veitch J, Vorvick C, Vyachanin SP, Wallace L, Ward H, Ward R, Watts K, Webber D, Weiland U, Weinstein A, Weiss R, Wen S, Wette K, Whelan JT, Whitcomb SE, Whiting BF, Wiley S, Wilkinson C, Willems PA, Willke B, Wilson A, Winkler W, Wise S, Wiseman AG, Woan G, Woods D, Wooley R, Worden J, Yakushin I, Yamamoto H, Yoshida S, Zanolin M, Zhang L, Zotov N, Zucker M, Zweizig J. Upper limits on a stochastic background of gravitational waves. Phys Rev Lett 2005; 95:221101. [PMID: 16384203 DOI: 10.1103/physrevlett.95.221101] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2005] [Indexed: 05/05/2023]
Abstract
The Laser Interferometer Gravitational-Wave Observatory has performed a third science run with much improved sensitivities of all three interferometers. We present an analysis of approximately 200 hours of data acquired during this run, used to search for a stochastic background of gravitational radiation. We place upper bounds on the energy density stored as gravitational radiation for three different spectral power laws. For the flat spectrum, our limit of omega0 < 8.4 x 10(-4) in the 69-156 Hz band is approximately 10(5) times lower than the previous result in this frequency range.
Collapse
Affiliation(s)
- B Abbott
- LIGO-California Institute of Technology, Pasadena, California 91125, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abbott B, Abbott R, Adhikari R, Ageev A, Allen B, Amin R, Anderson SB, Anderson WG, Araya M, Armandula H, Ashley M, Asiri F, Aufmuth P, Aulbert C, Babak S, Balasubramanian R, Ballmer S, Barish BC, Barker C, Barker D, Barnes M, Barr B, Barton MA, Bayer K, Beausoleil R, Belczynski K, Bennett R, Berukoff SJ, Betzwieser J, Bhawal B, Bilenko IA, Billingsley G, Black E, Blackburn K, Blackburn L, Bland B, Bochner B, Bogue L, Bork R, Bose S, Brady PR, Braginsky VB, Brau JE, Brown DA, Bullington A, Bunkowski A, Buonanno A, Burgess R, Busby D, Butler WE, Byer RL, Cadonati L, Cagnoli G, Camp JB, Cantley CA, Cardenas L, Carter K, Casey MM, Castiglione J, Chandler A, Chapsky J, Charlton P, Chatterji S, Chelkowski S, Chen Y, Chickarmane V, Chin D, Christensen N, Churches D, Cokelaer T, Colacino C, Coldwell R, Coles M, Cook D, Corbitt T, Coyne D, Creighton JDE, Creighton TD, Crooks DRM, Csatorday P, Cusack BJ, Cutler C, D'Ambrosio E, Danzmann K, Daw E, DeBra D, Delker T, Dergachev V, DeSalvo R, Dhurandhar S, Di Credico A, Díaz M, Ding H, Drever RWP, Dupuis RJ, Edlund JA, Ehrens P, Elliffe EJ, Etzel T, Evans M, Evans T, Fairhurst S, Fallnich C, Farnham D, Fejer MM, Findley T, Fine M, Finn LS, Franzen KY, Freise A, Frey R, Fritschel P, Frolov VV, Fyffe M, Ganezer KS, Garofoli J, Giaime JA, Gillespie A, Goda K, González G, Gossler S, Grandclément P, Grant A, Gray C, Gretarsson AM, Grimmett D, Grote H, Grunewald S, Guenther M, Gustafson E, Gustafson R, Hamilton WO, Hammond M, Hanson J, Hardham C, Harms J, Harry G, Hartunian A, Heefner J, Hefetz Y, Heinzel G, Heng IS, Hennessy M, Hepler N, Heptonstall A, Heurs M, Hewitson M, Hild S, Hindman N, Hoang P, Hough J, Hrynevych M, Hua W, Ito M, Itoh Y, Ivanov A, Jennrich O, Johnson B, Johnson WW, Johnston WR, Jones DI, Jones L, Jungwirth D, Kalogera V, Katsavounidis E, Kawabe K, Kawamura S, Kells W, Kern J, Khan A, Killbourn S, Killow CJ, Kim C, King C, King P, Klimenko S, Koranda S, Kötter K, Kovalik J, Kozak D, Krishnan B, Landry M, Langdale J, Lantz B, Lawrence R, Lazzarini A, Lei M, Leonor I, Libbrecht K, Libson A, Lindquist P, Liu S, Logan J, Lormand M, Lubinski M, Lück H, Lyons TT, Machenschalk B, MacInnis M, Mageswaran M, Mailand K, Majid W, Malec M, Mann F, Marin A, Márka S, Maros E, Mason J, Mason K, Matherny O, Matone L, Mavalvala N, McCarthy R, McClelland DE, McHugh M, McNabb JWC, Mendell G, Mercer RA, Meshkov S, Messaritaki E, Messenger C, Mitrofanov VP, Mitselmakher G, Mittleman R, Miyakawa O, Miyoki S, Mohanty S, Moreno G, Mossavi K, Mueller G, Mukherjee S, Murray P, Myers J, Nagano S, Nash T, Nayak R, Newton G, Nocera F, Noel JS, Nutzman P, Olson T, O'Reilly B, Ottaway DJ, Ottewill A, Ouimette D, Overmier H, Owen BJ, Pan Y, Papa MA, Parameshwaraiah V, Parameswariah C, Pedraza M, Penn S, Pitkin M, Plissi M, Prix R, Quetschke V, Raab F, Radkins H, Rahkola R, Rakhmanov M, Rao SR, Rawlins K, Ray-Majumder S, Re V, Redding D, Regehr MW, Regimbau T, Reid S, Reilly KT, Reithmaier K, Reitze DH, Richman S, Riesen R, Riles K, Rivera B, Rizzi A, Robertson DI, Robertson NA, Robison L, Roddy S, Rollins J, Romano JD, Romie J, Rong H, Rose D, Rotthoff E, Rowan S, Rüdiger A, Russell P, Ryan K, Salzman I, Sandberg V, Sanders GH, Sannibale V, Sathyaprakash B, Saulson PR, Savage R, Sazonov A, Schilling R, Schlaufman K, Schmidt V, Schnabel R, Schofield R, Schutz BF, Schwinberg P, Scott SM, Seader SE, Searle AC, Sears B, Seel S, Seifert F, Sengupta AS, Shapiro CA, Shawhan P, Shoemaker DH, Shu QZ, Sibley A, Siemens X, Sievers L, Sigg D, Sintes AM, Smith JR, Smith M, Smith MR, Sneddon PH, Spero R, Stapfer G, Steussy D, Strain KA, Strom D, Stuver A, Summerscales T, Sumner MC, Sutton PJ, Sylvestre J, Takamori A, Tanner DB, Tariq H, Taylor I, Taylor R, Taylor R, Thorne KA, Thorne KS, Tibbits M, Tilav S, Tinto M, Tokmakov KV, Torres C, Torrie C, Traylor G, Tyler W, Ugolini D, Ungarelli C, Vallisneri M, van Putten M, Vass S, Vecchio A, Veitch J, Vorvick C, Vyachanin SP, Wallace L, Walther H, Ward H, Ware B, Watts K, Webber D, Weidner A, Weiland U, Weinstein A, Weiss R, Welling H, Wen L, Wen S, Whelan JT, Whitcomb SE, Whiting BF, Wiley S, Wilkinson C, Willems PA, Williams PR, Williams R, Willke B, Wilson A, Winjum BJ, Winkler W, Wise S, Wiseman AG, Woan G, Wooley R, Worden J, Wu W, Yakushin I, Yamamoto H, Yoshida S, Zaleski KD, Zanolin M, Zawischa I, Zhang L, Zhu R, Zotov N, Zucker M, Zweizig J, Kramer M, Lyne AG. Limits on gravitational-wave emission from selected pulsars using LIGO data. Phys Rev Lett 2005; 94:181103. [PMID: 15904354 DOI: 10.1103/physrevlett.94.181103] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/29/2004] [Indexed: 05/02/2023]
Abstract
We place direct upper limits on the amplitude of gravitational waves from 28 isolated radio pulsars by a coherent multidetector analysis of the data collected during the second science run of the LIGO interferometric detectors. These are the first direct upper limits for 26 of the 28 pulsars. We use coordinated radio observations for the first time to build radio-guided phase templates for the expected gravitational-wave signals. The unprecedented sensitivity of the detectors allows us to set strain upper limits as low as a few times 10(-24). These strain limits translate into limits on the equatorial ellipticities of the pulsars, which are smaller than 10(-5) for the four closest pulsars.
Collapse
Affiliation(s)
- B Abbott
- LIGO-California Institute of Technology, Pasadena, CA 91125, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Malec M, van der Velden VHJ, Björklund E, Wijkhuijs JM, Söderhäll S, Mazur J, Björkholm M, Porwit-MacDonald A. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia 2004; 18:1630-6. [DOI: 10.1038/sj.leu.2403444] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
15
|
van der Velden VHJ, Boeckx N, Gonzalez M, Malec M, Barbany G, Lion T, Gottardi E, Pallisgaard N, Beillard E, Hop WCJ, Hoogeveen PG, Gabert J, van Dongen JJM. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program. Leukemia 2004; 18:884-6. [PMID: 14961029 DOI: 10.1038/sj.leu.2403309] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JLE, De Micheli D, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJM. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program. Leukemia 2003; 17:2318-57. [PMID: 14562125 DOI: 10.1038/sj.leu.2403135] [Citation(s) in RCA: 1106] [Impact Index Per Article: 52.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Detection of minimal residual disease (MRD) has proven to provide independent prognostic information for treatment stratification in several types of leukemias such as childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and acute promyelocytic leukemia. This report focuses on the accurate quantitative measurement of fusion gene (FG) transcripts as can be applied in 35-45% of ALL and acute myeloid leukemia, and in more than 90% of CML. A total of 26 European university laboratories from 10 countries have collaborated to establish a standardized protocol for TaqMan-based real-time quantitative PCR (RQ-PCR) analysis of the main leukemia-associated FGs within the Europe Against Cancer (EAC) program. Four phases were scheduled: (1) training, (2) optimization, (3) sensitivity testing and (4) patient sample testing. During our program, three quality control rounds on a large series of coded RNA samples were performed including a balanced randomized assay, which enabled final validation of the EAC primer and probe sets. The expression level of the nine major FG transcripts in a large series of stored diagnostic leukemia samples (n=278) was evaluated. After normalization, no statistically significant difference in expression level was observed between bone marrow and peripheral blood on paired samples at diagnosis. However, RQ-PCR revealed marked differences in FG expression between transcripts in leukemic samples at diagnosis that could account for differential assay sensitivity. The development of standardized protocols for RQ-PCR analysis of FG transcripts provides a milestone for molecular determination of MRD levels. This is likely to prove invaluable to the management of patients entered into multicenter therapeutic trials.
Collapse
Affiliation(s)
- J Gabert
- Department of Hematology Biology, Institut Paoli Calmettes, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Fuchsjäger-Mayrl G, Malec M, Amoako-Mensah T, Kolodjaschna J, Schmetterer L. Changes in choroidal blood flow during light/dark transitions are not altered by atropine or propranolol in healthy subjects. Vision Res 2003; 43:2185-90. [PMID: 12855253 DOI: 10.1016/s0042-6989(03)00332-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
It has recently been reported that light/dark transitions lead to changes in choroidal blood flow. Several observations indicate that these changes in choroidal perfusion are triggered at least in part by neural mechanisms. In the present study we hypothesised that the choroidal blood flow response to changes in retinal illumination may be modified by either the muscarinic receptor antagonist atropine or by the beta-receptor antagonist propranolol. In 15 healthy subjects the response of choroidal perfusion was studied in a randomised placebo-controlled three way cross-over study using laser Doppler flowmetry and laser interferometric measurement of fundus pulsation amplitude. Before drug administration a transition from light to dark reduced both choroidal haemodynamic parameters by 8%-12%. Neither propranolol nor atropine altered basal choroidal blood flow or choroidal blood flow responses to light/dark transitions. Our data indicate that neither muscarinic nor beta-receptors are involved in the choroidal blood flow response to changes in retinal illumination. Further studies are required to elucidate which mechanisms contribute to this blood flow behaviour of the choroid.
Collapse
Affiliation(s)
- Gabriele Fuchsjäger-Mayrl
- Department of Clinical Pharmacology, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria
| | | | | | | | | |
Collapse
|
18
|
Homoncik M, Malec M, Marsik C, Sycha T, Anzenhofer S, Gustorff B, Jilma B. Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clin Exp Rheumatol 2003; 21:229-31. [PMID: 12747281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
OBJECTIVE Although rofecoxib has very high selectivity for cyclo-oxygenase 2 (COX-2), supratherapeutic rofecoxib concentrations (> 1000 mg) inhibit purified human COX-1 in vitro and TXB2 formation in vivo. It is therefore possible that higher doses of rofecoxib may affect platelet function. This could be important if rofecoxib is given to thrombocytopenic patients. In these cases, already moderate inhibition of platelet function could precipitate bleeding complications. We therefore set out to investigate the influence of rofecoxib on platelet function in healthy volunteers. METHODS We set up a balanced-randomised, double-blind, placebo-controlled, two way cross-over study. Peripheral blood was withdrawn from 42 healthy volunteers before and 3 hours after intake of 50, 250, 500 mg of rofecoxib or placebo (n = 14 per group). Platelet function was assessed by a platelet function analyzer (PFA-100) which measures collagen-epinephrine induced closure time (CEPI-CT) under shear stress. RESULTS CEPI-CT increased by 14% (p = 0.002) and 11% (p = 0.003) three hours after intake of placebo and rofecoxib at dosages of up to 500 mg, respectively. The increase in CEPI-CT versus baseline was not significantly different in the placebo period compared with the active treatment periods (n = 42, p > 0.05). CONCLUSIONS Rofecoxib does not impair platelet function. Thus, rofecoxib appears to be a valuable analgetic and antipyretic agent in the therapy of patients at risk for bleeding.
Collapse
Affiliation(s)
- M Homoncik
- Department of Clinical Pharmacology-TARGET, Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Vienna University, Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
19
|
Fuchsjäger-Mayrl G, Luksch A, Malec M, Polska E, Wolzt M, Schmetterer L. Role of endothelin-1 in choroidal blood flow regulation during isometric exercise in healthy humans. Invest Ophthalmol Vis Sci 2003; 44:728-33. [PMID: 12556405 DOI: 10.1167/iovs.02-0372] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
PURPOSE There is evidence that the choroid has some autoregulatory capacity in response to changes in ocular perfusion pressure (OPP). The mediators of this response are hitherto unidentified. The hypothesis for the current study was that endothelin (ET)-1 and/or angiotensin (ANF)-II may be involved in choroidal vasoconstriction during an increase in OPP. METHODS To test this hypothesis a randomized, double-masked, placebo-controlled, three way crossover study was performed in 12 healthy male volunteers. Subjects received on different study days intravenous infusions of the specific ET(A) receptor antagonist BQ-123, the angiotensin converting enzyme inhibitor enalapril or placebo. During these infusion periods subjects were asked to squat for 6 minutes. Choroidal blood flow was measured using a confocal laser Doppler flowmeter and ocular perfusion pressure (OPP) was calculated from mean arterial pressure and intraocular pressure. RESULTS BQ-123 and enalapril had no effect on basal blood pressure, pulse rate, intraocular pressure, or choroidal blood flow. During isometric exercise, a pronounced increase in mean arterial pressure paralleled by an increase in OPP was observed. Although choroidal blood flow slightly increased during squatting, the increase was much less pronounced than the increase in OPP, indicating some regulatory potential of the choroid. Enalapril did not alter the choroidal pressure-flow relationship during isometric exercise, but BQ-123 induced a significant leftward shift of the pressure-flow curve (P < 0.001). CONCLUSIONS The present data indicate that ET-1, but not ANG II, plays a role in choroidal blood flow regulation during isometric exercise in healthy humans. Hence, impaired choroidal autoregulation in patients with ocular vascular diseases may arise from an altered endothelin system. Further studies in such patients are warranted to verify this hypothesis.
Collapse
|
20
|
Fuchsjäger-Mayrl G, Malec M, Polska E, Jilma B, Wolzt M, Schmetterer L. Effects of granulocyte colony stimulating factor on retinal leukocyte and erythrocyte flux in the human retina. Invest Ophthalmol Vis Sci 2002; 43:1520-4. [PMID: 11980869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023] Open
Abstract
PURPOSE The blue-field entoptic technique was introduced more than 20 years ago to quantify perimacular white blood cell flux. However, a final confirmation that the perceived corpuscles represent leukocytes is still unavailable. METHODS The study design was randomized, placebo-controlled, and double masked with two parallel groups. Fifteen healthy male subjects received a single dose of granulocyte colony stimulating factor (G-CSF, 300 microg) and 15 other subjects received placebo. The following parameters were assessed at baseline and at 12 minutes and 8 hours after administration: retinal white blood cell flux, with the blue-field entoptic technique; retinal blood velocities, with bidirectional laser Doppler velocimetry; retinal venous diameter determined with a retinal vessel analyzer; and blood pressure and pulse rate determined by automated oscillometry and pulse oxymetry, respectively. RESULTS After 12 minutes, G-CSF reduced total leukocyte count from 5.5 +/- 1.4 10(9)/L at baseline to 1.9 +/- 0.4 10(9)/L. This was paralleled by a 35% +/- 11% decrease in retinal white blood cell density. After 8 hours G-CSF increased total leukocyte counts to 20.0 +/- 4.4 10(9)/L. Again, this increase in circulating leukocytes was reflected by an increase in retinal white blood cell density (110% +/- 48%). All effects were significant at P < 0.001. By contrast, none of the other hemodynamic parameters was changed by administration of G-CSF. CONCLUSIONS The results clearly indicate that the blue-field entoptic technique assesses leukocyte movement in the perimacular capillaries of the retina. Moreover, white blood cell density appears to adequately reflect the number of circulating leukocytes within the retinal microvasculature. Hence, an increase in retinal white blood cell density does not necessarily reflect retinal vasodilatation.
Collapse
Affiliation(s)
- Gabriele Fuchsjäger-Mayrl
- Department of Clinical Pharmacology, Vienna University, Währinger Gürtel 18-20, A-1090 Vienna, Austria
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
There is recent evidence that the perfusion of the choroid changes during dark-light transitions. We set out to investigate this response in more detail and to elucidate possible mechanisms involved in this process. For this purpose, the effect of dark-light transitions on choroidal perfusion was studied in healthy subjects. Choroidal blood flow and ocular fundus pulsation amplitude were measured as indices of choroidal perfusion during dark-light transitions using laser Doppler flowmetry and laser interferometry, respectively. In the first experiment, subjects were first kept in room light for 20 min, then light conditions were changed to darkness for 20 min, and thereafter, subjects were exposed to room light again. Both choroidal parameters decreased (-12% to -14%) during darkness but returned to baseline after the final room light period. In the second experiment, the index eye underwent the same procedure, whereas the contralateral eye was kept in light throughout the experiment. Choroidal haemodynamic parameters in the index eye reacted in a way comparable to that seen in the first experiment. The eye that was kept in light also reacted, but the effect tended to be less pronounced than that seen in the index eye (-8% to -10%). The observation that choroidal blood flow in both eyes reacts during unilateral light-dark transitions indicates that choroidal perfusion rate is adapted to retinal illumination conditions by neural control mechanisms.
Collapse
Affiliation(s)
- G Fuchsjäger-Mayrl
- Department of Clinical Pharmacology, University of Vienna, Vienna General Hospital, Währinger Gürtel 18-20, A-1090 Vienna, Austria
| | | | | | | |
Collapse
|
22
|
Malec M, Björklund E, Söderhäll S, Mazur J, Sjögren AM, Pisa P, Björkholm M, Porwit-MacDonald A. Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL. Leukemia 2001; 15:716-27. [PMID: 11368431 DOI: 10.1038/sj.leu.2402091] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The analysis of minimal residual disease (MRD) has assumed a growing role in the follow-up of patients with acute lymphoblastic leukemia (ALL). We have applied multiparameter flow cytometry (FC) with 'live-gate' analysis and allele-specific oligonucleotide (ASO)-PCR detecting leukemia-specific T cell receptor gamma and delta gene rearrangements for MRD follow-up in 30 ALL patients. The comparison of results obtained in 89 follow-up samples from 23 patients showed significantly consistent results in 70 samples (78%); (P < 0.001). Bone marrow samples taken during the first phase of treatment (during or immediately after induction) showed a lower level of consistency when compared to samples taken during later phases of treatment (69% vs 85% consistent results, respectively). Some of the discrepant results were due to low cellularity of the samples obtained for FC and some due to the presence of PCR inhibitors. Of 29 patients evaluated at the end of the induction treatment, 18 (62%) had detectable levels of MRD and six of these patients suffered relapse. In all these patients MRD levels by FC increased preceding relapse. Our results suggest that FC offers a MRD detection tool that can be easily applied in clinical practice and is as informative as molecular methods.
Collapse
Affiliation(s)
- M Malec
- Department of Pathology, Karolinska Hospital, Stockholm, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 49:71-7. [PMID: 11163499 DOI: 10.1016/s0360-3016(00)01458-9] [Citation(s) in RCA: 100] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
PURPOSE To report the results of a prospective Phase III trial for patients with newly diagnosed glioblastoma multiforme (GBM), treated with either accelerated hyperfractionated irradiation with or without difluromethylornithine (DFMO) or standard fractionated irradiation with or without DFMO. METHODS AND MATERIALS Adult patients with newly diagnosed GBM were registered and randomized following surgery to one of 4 treatment arms: Arm A, accelerated hyperfractionation alone using 2 fractions a day of 1.6 Gy to a total dose of 70.4 Gy in 44 fractions; Arm B, accelerated hyperfractionation as above plus DFMO 1.8 gm/m2 by mouth every 8 h beginning one week before radiation until the last fraction was given; Arm C, single-fraction irradiation of 1.8 Gy/day to 59.4 Gy; Arm D, single-fraction irradiation as in Arm C plus DFMO given as in Arm B. Patients were followed for progression-free survival (PFS) and overall survival (OS), as well as for toxicity. Eligibility required histologically proven GBM, age > or =18, Karnofsky performance status (KPS) > or =60, and no prior chemotherapy or radiotherapy. Adjuvant chemotherapy was not used in this protocol. RESULTS A total of 231 eligible patients were enrolled. There were 95 men and 136 women with a median age of 57 years, and median KPS of 90. Extent of resection was total in 23, subtotal in 152, and biopsy only in 56 patients. The 4 arms were balanced with respect to age, KPS, and extent of resection. Times to event measurements are from date of diagnosis. Median OS and PFS were 40 and 19 weeks for Arm A; 42 and 22 weeks for Arm B; 37 and 16 weeks for Arm C; and 44 and 19 weeks for Arm D (p = 0.48 for survival; p = 0.32 for PFS). Comparison of the 2 arms treated with DFMO to the 2 arms without DFMO revealed no difference in OS (37 weeks vs. 42 weeks, p = 0.12) or PFS and thus no benefit to the use of DFMO. Comparison of the 2 standard fractionation arms to the 2 accelerated hyperfractionation arms also resulted in no difference in OS (42 weeks vs. 41 weeks, p = 0.75) or PFS, showing no benefit to accelerated hyperfractionated irradiation. CONCLUSION In this prospective Phase III study, no survival or PFS benefit was seen with accelerated hyperfractionated irradiation to 70.4 Gy, nor was any benefit seen with DFMO as a radiosensitizer. Standard fractionated irradiation to 59.4 Gy remains the treatment of choice for newly diagnosed patients with glioblastoma multiforme.
Collapse
Affiliation(s)
- M D Prados
- Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143-0372, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Hellström AC, Blegen H, Malec M, Silfverswärd C, Lystad S, Børresen-Dale AL, Auer G. Recurrent fallopian tube carcinoma: TP53 mutation and clinical course. Int J Gynecol Pathol 2000; 19:145-51. [PMID: 10782411 DOI: 10.1097/00004347-200004000-00008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Primary fallopian tube carcinoma is a rare, aggressive gynecological cancer; little is known about its cause. Previous studies have indicated that p53 immunopositivity is correlated with short-term survival in primary fallopian tube carcinoma. We examined p53 and p21/WAF1 immunostaining and TP53 mutation in exons 5 to 8 by single-stranded conformation polymorphism and constant denaturant gel electrophoresis in nine cases of primary fallopian tube carcinoma and their metastases/recurrences from patients who survived for between a few months and more than 20 years after diagnosis. We found that 1.) p53 immunopositivity without detectable p21/WAF1 immunostaining did not correlate with TP53 mutations in the conserved domains; 2.) mutations in TP53 occurred in two metastases/recurrences but not in their corresponding primary tumors; 3.) in two cancers, a TP53 mutation was observed in the primary tumor but not in the metastases/recurrences; 4.) constant denaturant gel electrophoresis seems to be more sensitive than single-stranded conformation polymorphism in detecting TP53 mutations; and 5.) in the nine cases studied, p53 immunoreactivity and/or TP53 mutation analysis did not correlate with tumor progression, survival, or response to treatment.
Collapse
Affiliation(s)
- A C Hellström
- Department of Gynaecological Oncology, Karolinska Hospital and Institutet, Stockholm, Sweden
| | | | | | | | | | | | | |
Collapse
|
25
|
Levin VA, Lamborn K, Wara W, Davis R, Edwards M, Rabbitt J, Malec M, Prados MD. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children. Neuro Oncol 2000; 2:22-8. [PMID: 11302250 PMCID: PMC1920700 DOI: 10.1093/neuonc/2.1.22] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
We conducted a single-arm phase II study to evaluate the efficacy and safety of radiotherapy combined with 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine (TPDCV) chemotherapy for treating malignant astrocytoma in children and anaplastic ependymoma in patients of all ages. Between 1984 and 1992, 42 patients who had malignant astrocytomas (glioblastomas multiforme, anaplastic astrocytomas, or mixed anaplastic oligoastrocytomas) were treated with TPDCV chemotherapy and radiation therapy. Of these patients, 40 were younger than 18 years, but 2 were older (22 and 23 years) when treated. Cranial radiation averaged 58 Gy. TPDCV chemotherapy was given for 1 year or until progression. Between 1989 and 1991, 17 patients with malignant ependymoma were treated with TPDCV chemotherapy and craniospinal radiation. Radiation was given at an average dose of 54 Gy to the tumor, 28 Gy to the whole brain, and 31 Gy to the spinal axis. TPDCV chemotherapy was given for 1 year or until tumor progressed. Of the patients with glioblastoma multiforme, 13 of 17 died; the median time to progression was 49 weeks, and median survival was 85 weeks. The four patients surviving at this writing were followed a median 537 weeks (range 364-635 weeks). Of the patients with nonglioblastoma malignant astrocytoma, 14 of 25 died; the median time to progression was 224 weeks. Median survival was not reached in this group. The median follow-up for those surviving was 494 weeks. For the patients with ependymoma, 11 of 17 died with a median time to progression of 141 weeks. The median follow-up for the eight who survive was 469 weeks. Nine patients died with a median survival of 183 weeks. The combination of TPDCV and radiotherapy has activity against childhood anaplastic astrocytoma, glioblastoma multiforme, and anaplastic ependymoma. The results of this study for children with glioblastoma were comparable to results in the literature, while the results for children with anaplastic astrocytoma appeared better than most reports. The combination of TPDCV chemotherapy and radiation therapy for anaplastic ependymomas appears to be active and at least as good as published reports using radiation therapy alone.
Collapse
Affiliation(s)
- V A Levin
- Brain Tumor Center and the Department of Neuro-Oncology, Houston, TX 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
26
|
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diáz MG, Malec M, Langerak AW, San Miguel JF, Biondi A. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13:1901-28. [PMID: 10602411 DOI: 10.1038/sj.leu.2401592] [Citation(s) in RCA: 794] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Prospective studies on the detection of minimal residual disease (MRD) in acute leukemia patients have shown that large-scale MRD studies are feasible and that clinically relevant MRD-based risk group classification can be achieved and can now be used for designing new treatment protocols. However, multicenter international treatment protocols with MRD-based stratification of treatment need careful standardization and quality control of the MRD techniques. This was the aim of the European BIOMED-1 Concerted Action 'Investigation of minimal residual disease in acute leukemia: international standardization and clinical evaluation' with participants of 14 laboratories in eight European countries (ES, NL, PT, IT, DE, FR, SE and AT). Standardization and quality control was performed for the three main types of MRD techniques, ie flow cytometric immunophenotyping, PCR analysis of antigen receptor genes, and RT-PCR analysis of well-defined chromosomal aberrations. This study focussed on the latter MRD technique. A total of nine well-defined chromosome aberrations with fusion gene transcripts were selected: t(1;19) with E2A-PBX1, t(4;11) with MLL-AF4, t(8;21) with AML1-ETO, t(9;22) with BCR-ABL p190 and BCR-ABL p210, t(12;21) with TEL-AML1, t(15;17) with PML-RARA, inv (16) with CBFB-MYH11, and microdeletion 1p32 with SIL-TAL1. PCR primers were designed according to predefined criteria for single PCR (external primers A <--> B) and nested PCR (internal primers C <--> D) as well as for 'shifted' PCR with a primer upstream (E5' primer) or downstream (E3' primer) of the external A <--> B primers. The 'shifted' E primers were designed for performing an independent PCR together with one of the internal primers for confirmation (or exclusion) of positive results. Various local RT and PCR protocols were compared and subsequently a common protocol was designed, tested and adapted, resulting in a standardized RT-PCR protocol. After initial testing (with adaptations whenever necessary) and approval by two or three laboratories, the primers were tested by all participating laboratories, using 17 cell lines and patient samples as positive controls. This testing included comparison with local protocols and primers as well as sensitivity testing via dilution experiments. The collaborative efforts resulted in standardized primer sets with a minimal target sensitivity of 10-2 for virtually all single PCR analyses, whereas the nested PCR analyses generally reached the minimal target sensitivity of 10-4. The standardized RT-PCR protocol and primer sets can now be used for molecular classification of acute leukemia at diagnosis and for MRD detection during follow-up to evaluate treatment effectiveness.
Collapse
Affiliation(s)
- J J van Dongen
- Department of Immunology, University Hospital Rotterdam/Erasmus University Rotterdam, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Zietek E, Sieczka J, Malec M, Wasilewska M. [Surgical treatment of hypopharyngeal cancer: reconstructive methods]. Otolaryngol Pol 1998; 52:251-7. [PMID: 9760764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The paper presents a 26-year experience of the ENT Clinic of the Pomeranian Medical Academy in Szczecin with 20 patients who underwent reconstruction of the hypopharynx after resection for locally advanced carcinoma. The procedures were carried out in years 1970-1995. The reconstructions included 7 musculomucosal pedicle flaps obtained from the base of the tongue, 5 epiglottis pedicle flaps, 4 tubed pectoralis major musculocutaneous flaps, 1 vascular pedicle submandibular gland flap, 1 deltopectoral flap, 1 skin flap and 1 island pectoralis major musculocutaneous flap. An analysis of the procedures with emphasis on the oncological and functional results indicates that each techniques has advantages in specific circumstances. Guidelines for the application of the techniques are described.
Collapse
Affiliation(s)
- E Zietek
- Katedra i Klinika Otolaryngologii PAM w Szczecinie
| | | | | | | |
Collapse
|
28
|
Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados MD. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1998; 16:2188-94. [PMID: 9626220 DOI: 10.1200/jco.1998.16.6.2188] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma. PATIENTS AND METHODS Patients were stratified by starting dose of paclitaxel and concurrent anticonvulsant (AC) use and were treated in cohorts of three patients. The starting dose was 240 mg/m2 administered intravenously with escalations of 30 mg/m2 until the MTD was established. Pharmacokinetic data were obtained for each patient for the first infusion. Tumor response was assessed at 6-week intervals and treatment was continued until documented tumor progression, unacceptable toxicity, or a total of 12 paclitaxel infusions. RESULTS From April 1995 to December 1996, 34 patients were treated; 27 patients in the AC group and seven patients in the non-AC group. The MTD for patients who received ACs was established at 360 mg/m2 and the dose-limiting toxicity (DLT) was central neurotoxicity, characterized as transient encephalopathy and seizures. In contrast, the MTD for patients who did not receive ACs was 240 mg/m2, and myelosuppression, gastrointestinal toxicity, and fatigue were the DLTs. Pharmacokinetic data confirmed that the plasma drug levels and clearance rates were similar for patients in both groups at the respective dose levels that produced DLTs. CONCLUSION The pharmacokinetics of paclitaxel are altered by ACs, and significantly larger doses of the drug can be administered to patients with brain tumors on AC therapy. The toxicity profile is different for patients on AC therapy treated at these higher doses. A phase II study has been initiated that uses a dose of 330 mg/m2 for patients on AC therapy and 210 mg/m2 for patients not on AC therapy.
Collapse
Affiliation(s)
- S M Chang
- Department of Neurosurgery, University of California, San Francisco, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Zietek E, Malec M. [Deep neck infections in the antibiotic era]. Otolaryngol Pol 1998; 52:5-10. [PMID: 9591414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The paper presents 43 patients treated between 1971 and 1995 in the Otolaryngology Clinic of the Pomeranian Medical Academy in Szczecin because of deep neck space infections. The authors analyse their own clinical material paying particular attention to the diagnosis, microbiology, patients prognosis and basic therapeutic procedures. Out of the 43 cases, deaths occurred in 3, which denotes 7% mortality rate. The reason for failure was discussed. It was revealed that needle aspiration and sonography were for valuable to identify early abscess formation. The analyses have confirmed that the prognosis of the deep neck space infections is influenced by early diagnosis and prompt, extensive surgical treatment.
Collapse
Affiliation(s)
- E Zietek
- Katedra i Klinika Otolaryngologii PAM w Szczecinie
| | | |
Collapse
|
30
|
Malec M. [Rare tumors of the larynx]. Otolaryngol Pol 1998; 49 Suppl 20:426-7. [PMID: 9454199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Six cases of the rarely encountered, advanced tumours of the larynx treated in ENT Clinic of Pomeranian Medical Academy in Szczecin are presented: chondroma, rhabdomyosarcoma, neurinoma, cylindroma and 2 cases of granular cell tumour. There were certain diagnostic difficulties in rhabdomyosarcoma and chondroma cases. The immunocytochemical investigations were of decisive significance in differential diagnosis of the larynx sarcoma. In the case of chondroma there were problems with biopsy taking the tense tissue of the tumour was compressing the subglottic space. The radiological examinations turned out to be very helpful in this case. All patients were treated by surgery, two of them with rhabdomyosarcoma and cylindroma were treated by irradiation too. Observation periods were from 0.5 to 10 years. The oncological and functional results in 4 cases after partial laryngectomies turned out to be satisfactory. All larynx activities were preserved. The patient with sarcoma of the larynx died 6 years after diagnosis of neoplasm. Finally author discuss diagnostic problems and methods of treatment.
Collapse
Affiliation(s)
- M Malec
- Kliniki Otolaryngologicznej PAM, Szczecinie
| |
Collapse
|
31
|
Prados MD, Larson DA, Lamborn K, McDermott MW, Sneed PK, Wara WM, Chang SM, Mack EE, Krouwer HG, Chandler KL, Warnick RE, Davis RL, Rabbitt JE, Malec M, Levin VA, Gutin PH, Phillips TL, Wilson CB. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys 1998; 40:57-63. [PMID: 9422558 DOI: 10.1016/s0360-3016(97)00566-x] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE This study was designed to evaluate a combined modality treatment for malignant gliomas using radiation therapy with a radiosensitizer and an adjuvant chemotherapy regimen designed to modify resistance to BNCU. METHODS AND MATERIALS Patients were eligible if they were 15 years of age or older, and had newly diagnosed glioblastoma multiforme (GBM), or anaplastic glioma (AG). Treatment consisted of external beam radiotherapy given to a dose of 60 Gy using a single daily fraction Monday to Friday. Concurrent hydroxyurea at a dose of 300 mg/m2 every 6 h every other day was given during radiation. Following radiotherapy, patients were then treated with BCNU and 6-Thioguanine (6TG). The 6-TG was given by mouth every 6 h for 12 doses prior to BCNU. Patients were initially treated with 60 mg/m2/dose of 6TG, with escalation to a maximum dose of 100 mg/m2/dose. The primary study end points were time to tumor progression and survival. RESULTS A total of 245 eligible patients were enrolled from 1/18/88 to 12/26/91. The histologic subtypes included 135 GBM, and 110 with AG (103 with anaplastic astrocytoma, 7 with high-grade mixed oligoastrocytoma). For the GBM group, the median time to tumor progression (TTP) and median survival were 33 (95% CI 26, 39) and 56 (95% CI 49, 69) weeks, respectively. For the AG group the median TTP was 282 weeks (95% lower confidence bound = 155 weeks). Median survival for this group has not been reached (95% lower confidence bound = 284 weeks) with a median follow-up for surviving patients of 298 weeks. A proportional hazards model was used to look at potential prognostic factors for survival, including initial Karnofsky Performance Scale (KPS), age, and extent of surgery, as well as dose of 6TG. Higher KPS, and lower age, predicted for longer survival (p < 0.01, < 0.001) in GBM patients; lower age was significant (p = 0.05) for AG cases. A higher (greater than 95 mg/m2) or lower dose of 6TG was not statistically significant in this model. CONCLUSIONS This therapy was no more effective in patients with GBM than other reported series. In patients with malignant gliomas other than GBM, prolonged progression-free and overall survival is noted, without a median survival reached at the time of this report. In this subset of AG patients, survival is comparable to recent studies using halogenated prymidines during radiation and Procarbazine, CCNU, and Vincristine (PCV) as adjuvant chemotherapy.
Collapse
Affiliation(s)
- M D Prados
- Department of Neurosurgery, University of California San Francisco, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Munck-Wikland E, Blegen H, Lewensohn-Fuchs I, Malec M, Auer G, Kuylenstierna R, Dalianis T, Wiman K, Lindholm J. p53 overexpression in normal and dysplastic tissues adjacent to p53 negative squamous cell carcinomas of the head and neck. Int J Oncol 1997; 11:97-104. [DOI: 10.3892/ijo.11.1.97] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Affiliation(s)
- E Munck-Wikland
- KAROLINSKA HOSP,KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN. HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN VIROL,S-14186 HUDDINGE,SWEDEN. KAROLINSKA HOSP,KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN. DANDERYD HOSP,DEPT PATHOL,S-18288 DANDERYD,SWEDEN
| | - H Blegen
- KAROLINSKA HOSP,KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN. HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN VIROL,S-14186 HUDDINGE,SWEDEN. KAROLINSKA HOSP,KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN. DANDERYD HOSP,DEPT PATHOL,S-18288 DANDERYD,SWEDEN
| | - I Lewensohn-Fuchs
- KAROLINSKA HOSP,KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN. HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN VIROL,S-14186 HUDDINGE,SWEDEN. KAROLINSKA HOSP,KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN. DANDERYD HOSP,DEPT PATHOL,S-18288 DANDERYD,SWEDEN
| | - M Malec
- KAROLINSKA HOSP,KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN. HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN VIROL,S-14186 HUDDINGE,SWEDEN. KAROLINSKA HOSP,KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN. DANDERYD HOSP,DEPT PATHOL,S-18288 DANDERYD,SWEDEN
| | - G Auer
- KAROLINSKA HOSP,KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN. HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN VIROL,S-14186 HUDDINGE,SWEDEN. KAROLINSKA HOSP,KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN. DANDERYD HOSP,DEPT PATHOL,S-18288 DANDERYD,SWEDEN
| | - R Kuylenstierna
- KAROLINSKA HOSP,KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN. HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN VIROL,S-14186 HUDDINGE,SWEDEN. KAROLINSKA HOSP,KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN. DANDERYD HOSP,DEPT PATHOL,S-18288 DANDERYD,SWEDEN
| | - T Dalianis
- KAROLINSKA HOSP,KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN. HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN VIROL,S-14186 HUDDINGE,SWEDEN. KAROLINSKA HOSP,KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN. DANDERYD HOSP,DEPT PATHOL,S-18288 DANDERYD,SWEDEN
| | - K Wiman
- KAROLINSKA HOSP,KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN. HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN VIROL,S-14186 HUDDINGE,SWEDEN. KAROLINSKA HOSP,KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN. DANDERYD HOSP,DEPT PATHOL,S-18288 DANDERYD,SWEDEN
| | - J Lindholm
- KAROLINSKA HOSP,KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN. HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN VIROL,S-14186 HUDDINGE,SWEDEN. KAROLINSKA HOSP,KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN. DANDERYD HOSP,DEPT PATHOL,S-18288 DANDERYD,SWEDEN
| |
Collapse
|
33
|
Dricu A, Wang M, Hjertman M, Malec M, Blegen H, Wejde J, Carlberg M, Larsson O. Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology 1997; 7:625-33. [PMID: 9254045 DOI: 10.1093/glycob/7.5.625] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
One or more mevalonate derivatives of non-sterol type have been proposed to be of indispensable importance for cell growth. Conceivable mevalonate-dependent mechanisms involved in growth control are farnesylation of Ras proteins, regulation of c-myc expression, and N-linked glycosylation of the IGF-1 receptor. The latter mechanism might be rate-limited by dolichyl phosphate, which acts as a donor of oligosaccharides in glycoprotein synthesis in the endoplasmic reticulum. In order to study the significance for cell proliferation of the three aforementioned mevalonate-dependent processings, their inhibitory response due to mevalonate deprivation was explored and compared with the effect on DNA synthesis in the malignant melanoma cell line SK-MEL-2. We found that mevalonate depletion due to treatment with 3 microM lovastatin for 24 h, which efficiently growth-arrested the cells, hardly at all affected the expression of c-myc, and although Ras prenylation was inhibited by 50%, the most pronounced effect of lovastatin was seen on N-linked glycosylation of IGF-1 receptors, which was inhibited by more than 95%. The order and magnitude of the decreased IGF-1 receptor glycosylation, which was followed by a decreased expression of IGF-1 receptors at the cell membrane, correlated well with the inhibition of DNA synthesis. We investigated whether dolichol, and in particular dolichyl phosphate, through its participation in N-linked glycosylation, act as regulators of IGF-1 receptor expression. First, we could confirm that exogenous dolichol became phosphorylated and in this form took part in the glycosylation processing. Secondly, we showed that dolichyl phosphate, in a dose-dependent manner, could increase the number of IGF-1 receptors at the cell membrane, simultaneously as DNA synthesis was stimulated. Taken together, our results provide direct evidence for an important role of dolichyl phosphate as a regulator of cell growth through limiting N-linked glycosylation of the IGF-1 receptor.
Collapse
Affiliation(s)
- A Dricu
- Department of Tumor Pathology, Karolinska Institutet, Stockholm, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
In a Phase II trial, 63 evaluable patients with recurrent glioma received i.v. infusions of carboplatin every 3 weeks beginning at a dose of 400 mg/m2. The dose was increased by 50 mg/m2 at each subsequent infusion until the maximum tolerated dose reached, as defined by a platelet count < 25,000/mm3 or an absolute neutrophil count (ANC) < 500/mm3. Treatment was then resumed at the previous dose level and continued until tumor progression occurred. There were 43 men and 20 women studied (mean age, 41 years; range, 6 months to 70.6 years). The combined response and stabilization rate was 29% for 31 patients with glioblastoma and 71.9% for 32 patients with other tumors; median time to tumor progression was 8.2 and 20.3 weeks and median survival was 25.9 and 58.3 weeks, respectively. Twenty patients had level 4 platelet toxicity and nine had level 4 ANC toxicity. Most tumors progressed before the maximum tolerated dose was reached. These results were not better than those from a previous trial of carboplatin at an initial dose of 350 mg/m2, which was escalated by 25 mg/ m2 after every two infusions. Therefore, an optimal dosing schedule was not achieved in this trial.
Collapse
Affiliation(s)
- M D Prados
- Department of Neurological Surgery, School of Medicine, University of California, San Francisco 94143-0112, USA
| | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Few patients with glioblastoma multiforme survive more than 5 years. To identify the factors associated with long-term survival, patients with primary supratentorial glioblastoma multiforme diagnosed between 1969 and 1985 were identified from our computer data base. Twenty-two (5%) of the 449 patients identified survived at least 5 years after surgical diagnosis. There were 12 female and 10 male patients, with a mean age of 39.2 years (range, 15 to 63 yr). Twenty patients had a subtotal resection, and 2 had a gross total resection. The median duration of survival was 9.4 years. As of August 1, 1992, 10 patients were alive 5.2 to 13.6 years after diagnosis, and 1 patient was lost to follow-up after 9.4 years. Ten patients died from their tumors; 2 patients with stable tumors died, 1 from a ruptured intracranial aneurysm and 1 from erythromycin-induced hepatitis. Unusual sequelae were noted in irradiated areas in several cases. One patient had a scalp sarcoma and a basal cell carcinoma, and three patients had strokes; each of these events occurred more than 5 years after diagnosis. We conclude that among patients with glioblastoma multiforme, long-term survival is most likely for those who have a long disease-free interval after the initial diagnosis and receive multimodal therapy, including aggressive tumor removal. Other factors associated with long-term survival were younger age and high Karnofsky scores.
Collapse
Affiliation(s)
- K L Chandler
- Department of Neurological Surgery, School of Medicine, University of California, San Francisco
| | | | | | | |
Collapse
|
36
|
Abstract
BACKGROUND Oral eflornithine in combination with intravenous mitoguazone (methylbisguanylhydrazone) has shown activity against recurrent anaplastic gliomas. Eflornithine alone, however, has not been evaluated against recurrent gliomas. PURPOSE This study compared the antitumor activity of oral eflornithine with that of oral eflornithine combined with intravenous mitoguazone in the treatment of patients with recurrent or progressive glioblastoma multiforme as well as nonglioblastoma anaplastic gliomas. METHODS During the 1st year of therapy with eflornithine alone, the drug was given at a dose of 3.6 g/m2 on days 1-14, 22-35, and 43-56 every 8 hours; cycles were repeated every 63 days until progression. For the 2nd year, the drug was given on days 1-14, 29-42, and 57-70, with 84 days between cycles. For the 1st and 2nd years of eflornithine-mitoguazone therapy, eflornithine was given at 1.8 g/m2 on the same schedule. Mitoguazone was given intravenously at 200 mg/m2 on the final day of each 2-week sequence of eflornithine therapy. Response was determined by evaluating changes in the size of contrast-enhanced neuroimages. RESULTS Because of two cases of lethal hepatic necrosis, the initial random allocation of patients to the eflornithine-mitoguazone arm was stopped after 23 patients had been accrued. Ninety-eight patients were entered in the eflornithine arm; 80 patients (36 glioblastoma multiforme patients and 44 anaplastic glioma patients) were assessable for response. Antitumor activity (partial response, minor response, and stable disease) was seen in 45% of the patients with anaplastic gliomas, for a median of 49 weeks, but in only 17% of patients with glioblastoma multiforme (median not attained). Twenty-one (20%) of the patients with anaplastic glioma and 33% of the patients with glioblastoma multiforme were removed from the study before completing the first 8-week course of therapy because of neurological deterioration and tumor progression by the 5th week of treatment. CONCLUSION This study suggests that eflornithine alone is an effective palliative therapy for recurrent anaplastic gliomas. Additional studies are needed to confirm our finding.
Collapse
Affiliation(s)
- V A Levin
- Department of Neuro-oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030
| | | | | | | | | | | |
Collapse
|
37
|
Scharfen CO, Sneed PK, Wara WM, Larson DA, Phillips TL, Prados MD, Weaver KA, Malec M, Acord P, Lamborn KR. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 1992; 24:583-91. [PMID: 1429079 DOI: 10.1016/0360-3016(92)90702-j] [Citation(s) in RCA: 159] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A total of 307 adult patients with glioma were treated with high-activity removable iodine-125 interstitial brain implants at the University of California at San Francisco from December 1979 to June 1990. Recurrent gliomas underwent brain implant alone whereas previously untreated (primary) tumors underwent brain implant boost after external beam radiotherapy. Of these patients, 106 had primary glioblastoma multiforme, 68 had primary non-glioblastoma glioma, 66 had recurrent glioblastoma multiforme and 67 had recurrent nonglioblastoma glioma. Median follow-up for living patients was 143 weeks. Median survival from diagnosis for primary glioblastoma multiforme and high and low grade nonglioblastoma glioma was 88 weeks, 142 weeks, and 226 weeks, respectively. Median survival measured from the date of implant for recurrent glioblastoma multiforme and high and low grade nonglioblastoma glioma was 49 weeks, 52 weeks, and 81 weeks, respectively. Ninety-two percent of patients had no toxicity or transient acute side effects. Severe acute toxicity was seen in 6% of patients, life threatening acute toxicity in 1% of patients, and fatal toxicity in less than 1% of patients. Forty percent of patients with malignant glioma underwent reoperation at a median of 33 weeks after brain implant, with tumor found in 95% of specimens at reoperation. This large experience demonstrates that interstitial implant is well-tolerated and prolongs survival in patients with primary and recurrent glioblastoma multiforme, as evidenced by the 3-year survival rates of 22% and 15%, respectively.
Collapse
Affiliation(s)
- C O Scharfen
- Department of Radiation Oncology, University of California, San Francisco 94143-0226
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Carlson RW, Doroshow JH, Odujinrin OO, Flam MS, Malec M, Lamborn KR. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group. Invest New Drugs 1990; 8:387-9. [PMID: 2150672 DOI: 10.1007/bf00198597] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- R W Carlson
- Department of Medicine, Stanford University, CA 94305
| | | | | | | | | | | |
Collapse
|
39
|
John M, Flam M, Sikic B, Rotman M, Cooper J, Malec M, Hannigan J, Phillips T. Preliminary results of concurrent radiotherapy and chemotherapy in advanced cervical carcinoma: a phase I-II prospective intergroup NCOG-RTOG Study. Gynecol Oncol 1990; 37:1-5. [PMID: 2108909 DOI: 10.1016/0090-8258(90)90296-w] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Thirty-eight patients with advanced carcinoma of the cervix were prospectively treated with a concurrent combination of radiotherapy (RT) and chemotherapy (CT) using the drugs 5-fluorouracil (5FU), mitomycin C and cis-platinum as part of a Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group (RTOG) intergroup study. RT consisted of 36.00 Gy to the pelvis in 4 weeks followed by a 9.00-Gy parametrial boost. This was followed by two intracavitary applications for a total of 4000 mg hr of radium equivalent when possible. 5FU (1000 mg/m2/24 hr for 96 hr by iv infusion) and mitomycin C (10 mg/m2/iv bolus) were given during the second week of external RT. 5FU (dose as above) and cis-platinum (75 mg/m2/iv over 6 hr) were given during the first intracavitary application. Of 36 patients evaluable for toxicity, 11% had grade 3 nonhematological toxicity and 11% had reversible grade 4 hematological toxicity. There were no toxic deaths. A complete response rate of 62.5% was obtained overall (median survival not reached). This study suggests that this particular combination of RT and CT in advanced cervical carcinoma is effective and well tolerated.
Collapse
Affiliation(s)
- M John
- San Joaquin Valley CCOP, Fresno Community Hospital, California
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Gandara DR, Perez EA, Wold H, Caggiano V, Malec M, Ahn DK, Meyers F, Carlson RW. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol 1990; 27:243-7. [PMID: 2176134 DOI: 10.1007/bf00685721] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
To investigate chemotherapeutic dose intensity in advanced non-small-cell lung cancer (NSCLC), we evaluated a pharmacokinetically designed schedule of high-dose cisplatin (200 mg/m2 per 28-day cycle) plus mitomycin C. Between March 1987 and March 1989, 62 patients were registered for a phase II study of the Northern California Oncology Group (NCOG). The treatment schedule consisted of cisplatin in hypertonic saline given on a divided days 1 and 8 schedule (100 mg/m2 on each day) plus mitomycin C given at a dose of 8 mg/m2 on day 1 of each cycle. In 61 patients evaluable for response analysis, the overall response rate was 39% (24/61), with a complete response being achieved in 6% (4/61) of cases and a partial response, in 33% (20/61). The response according to reviewed histologic subtype included squamous, 53% of patients (10/19); large cell, 31% (4/13); and adenocarcinoma, 34% (10/29). The median survival for all patients was 29.3 weeks. The mean cisplatin and mitomycin C delivered dose intensities in this study were 45 mg/m2 per week (90% of the projected dose) and 1.5 mg/m2 per week (75%). The toxicity of this combination regimen in the 62 enrolled patients was significant but manageable. Leukopenia (WBC, less than 1,000/mm3) and thrombocytopenia (platelets, less than 25,000/mm3) occurred in 3% and 8% of patients treated, respectively. Dose-limiting renal toxicity and clinically significant ototoxicity developed in 8 patients each (13%), and a peripheral sensory neuropathy was observed in 17 cases (27%). Whether this type of dose-intensive therapy results in an improved therapeutic index in NSCLC is currently being evaluated in a randomized comparative trial versus standard-dose cisplatin therapy.
Collapse
Affiliation(s)
- D R Gandara
- Northern California Oncology Group, Northern California Cancer Center, Belmont
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Valone FH, Friedman MA, Wittlinger PS, Drakes T, Eisenberg PD, Malec M, Hannigan JF, Brown BW. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7:1427-36. [PMID: 2789272 DOI: 10.1200/jco.1989.7.10.1427] [Citation(s) in RCA: 145] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
We compared the effectiveness of fluorouracil (5-FU) alone (arm A), high-dose leucovorin plus 5-FU (arm B), and sequential methotrexate, 5-FU, and leucovorin (arm C) for treatment of patients with advanced colorectal carcinomas who had not received prior chemotherapy. Arm A consisted of infusions of 5-FU at 12 mg/kg/d intravenously (IV) for 5 days followed by weekly infusions of 5-FU at 15 mg/kg; arm B consisted of leucovorin infusions at 200 mg/m2/d IV plus infusions of 5-FU at 400 mg/m2/d IV on days 1 through 5 of a 28-day cycle; arm C consisted of methotrexate at 50 mg/m2 orally every 6 hours for five doses followed by infusions of 5-FU, 500 mg/m2 IV, and leucovorin, 10 mg/m2 orally, every 6 hours for five doses every other week. A total of 265 patients were entered into the trial, of whom 249 (94%) were fully evaluable. The objective response rate (complete [CR] plus partial [PR] responses) was 17.3% on arm A, 18.8% on arm B, and 19.8% on arm C (log-rank test, P greater than .4). The median time to failure was 138 days on arm A, 166 days on arm B, and 182 days on arm C (log-rank test, P values of arm A v B = .06; arm A v arm C = .04). Median survival was 345 days on arm A, 324 days on arm B, and 356 days on arm C (log-rank test, P greater than .4). Treatment with 5-FU alone was significantly more dose intensive and more toxic than either of the experimental combinations. The rates of grade 3 or greater nonhematologic toxicity were 42.3% on arm A, 24.3% on arm B, and 14.3% on arm C. Hematologic toxicity was milder but had the same pattern. This study indicates that these regimens of high-dose leucovorin plus 5-FU and sequential methotrexate, 5-FU, and leucovorin are not more effective than is 5-FU alone for treatment of patients with colorectal carcinomas when 5-FU is administered at high-dose intensity.
Collapse
|
42
|
Abstract
Mortality rates among 838 white female breast cancer patients were examined for relationships to personal characteristics assessed at time of diagnosis. These included weight and body mass index, oral contraceptive use, and prior menstrual and reproductive events. Multivariate analyses were used to determine the importance of these characteristics in predicting death rates specific for age and extent of disease at time of diagnosis. Weight was associated with poor prognosis among premenopausal patients, but not among postmenopausal patients. Premenopausal women weighing more than 140 lbs at diagnosis had death rates 1.7 times those of lighter women (P = 0.04). This effect was not explained by differences in the distribution of disease stage between the two groups. Body mass index was positively associated with mortality in both premenopausal and postmenopausal patients. In the entire group, the death rate ratio was 1.4 (P = 0.02) for obese (body mass index greater than 30.4 X 10(-3) lbs/in.2) vs lean women. Among premenopausal patients, parous women had higher mortality rates than nulliparous women (death rate ratio = 2.0, P = 0.06). Although the data were sparse, death rates were higher for women having a full-term pregnancy within 2 years of diagnosis than for premenopausal women with earlier pregnancies. Oral contraceptive use, age at menarche, age at first full term birth, and age at menopause were unrelated to mortality.
Collapse
Affiliation(s)
- J C Mohle-Boetani
- Department of Health Research and Policy, Stanford University School of Medicine, California 94305-5092
| | | | | | | | | | | |
Collapse
|
43
|
Abstract
Classical hydromagnetic theory predicts that the flow of dilute aqueous electrolyte in a slit can be stabilized by application of a strong, transverse magnetic field. However, recent experiments indicate that stabilization can be achieved with the use of a much weaker field in the presence of a small lateral current. A revised theory describes how the magnetic and electric fields interact to eliminate natural convection.
Collapse
|
44
|
|